Pyxis Oncology Inc. (PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, has a couple of catalysts to watch in the coming months.
The company's lead drug candidate is PYX-201, an investigational antibody-drug conjugate (ADC), which is under a phase I trial in multiple types of solid tumors. So far, 72 subjects have been dosed in the trial. Preliminary data, including efficacy, safety, and pharmacokinetics (PK) of PYX-201 is expected to be shared in the fall of 2024.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.